BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 21682151)

  • 1. Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in patients with left ventricular systolic dysfunction: 14 years after MADIT.
    Franqui-Rivera H; Sotomonte JC
    P R Health Sci J; 2011 Jun; 30(2):78-83. PubMed ID: 21682151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of implantable cardioverter-defibrillators.
    Sanders GD; Hlatky MA; Owens DK
    N Engl J Med; 2005 Oct; 353(14):1471-80. PubMed ID: 16207849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MADIT II, the Multi-center Autonomic Defibrillator Implantation Trial II stopped early for mortality reduction, has ICD therapy earned its evidence-based credentials?
    Coats AJ
    Int J Cardiol; 2002 Jan; 82(1):1-5. PubMed ID: 11786150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time dependence of defibrillator benefit after coronary revascularization in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II.
    Goldenberg I; Moss AJ; McNitt S; Zareba W; Hall WJ; Andrews ML; Wilber DJ; Klein HU;
    J Am Coll Cardiol; 2006 May; 47(9):1811-7. PubMed ID: 16682305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials.
    Ghanbari H; Dalloul G; Hasan R; Daccarett M; Saba S; David S; Machado C
    Arch Intern Med; 2009 Sep; 169(16):1500-6. PubMed ID: 19752408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relation of body mass index to sudden cardiac death and the benefit of implantable cardioverter-defibrillator in patients with left ventricular dysfunction after healing of myocardial infarction.
    Choy B; Hansen E; Moss AJ; McNitt S; Zareba W; Goldenberg I;
    Am J Cardiol; 2010 Mar; 105(5):581-6. PubMed ID: 20185000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2005; 5(14):1-74. PubMed ID: 23074465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction.
    Goldenberg I; Moss AJ; McNitt S; Zareba W; Andrews ML; Hall WJ; Greenberg H; Case RB;
    Am J Cardiol; 2006 Aug; 98(4):485-90. PubMed ID: 16893702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implantable cardioverter-defibrillator efficacy in patients with heart failure and left ventricular dysfunction (from the MADIT II population).
    Zareba W; Piotrowicz K; McNitt S; Moss AJ;
    Am J Cardiol; 2005 Jun; 95(12):1487-91. PubMed ID: 15950580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inverse relationship of blood pressure levels to sudden cardiac mortality and benefit of the implantable cardioverter-defibrillator in patients with ischemic left ventricular dysfunction.
    Goldenberg I; Moss AJ; McNitt S; Zareba W; Hall WJ; Andrews ML;
    J Am Coll Cardiol; 2007 Apr; 49(13):1427-33. PubMed ID: 17397670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implantable cardioverter defibrillator therapy for patients with less severe left ventricular dysfunction.
    Exner DV
    Curr Opin Cardiol; 2009 Jan; 24(1):61-7. PubMed ID: 19077818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proportion of patients followed in a specialized heart failure clinic needing an implantable cardioverter defibrillator as determined by applying different trial eligibility criteria.
    Toma M; McAlister FA; Ezekowitz J; Kimber S; Gulamhusein S; Pantano A; Sivakumaran S; Cujec B; Paterson I; Armstrong PW
    Am J Cardiol; 2006 Mar; 97(6):882-5. PubMed ID: 16516594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials.
    Nanthakumar K; Epstein AE; Kay GN; Plumb VJ; Lee DS
    J Am Coll Cardiol; 2004 Dec; 44(11):2166-72. PubMed ID: 15582314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population.
    Chan PS; Stein K; Chow T; Fendrick M; Bigger JT; Vijan S
    J Am Coll Cardiol; 2006 Jul; 48(1):112-21. PubMed ID: 16814657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II).
    Greenberg H; Case RB; Moss AJ; Brown MW; Carroll ER; Andrews ML;
    J Am Coll Cardiol; 2004 Apr; 43(8):1459-65. PubMed ID: 15093884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [14-year experience with implantable cardioverter/defibrillators: determination of prognosis and discharge behavior].
    Vester EG; Dees H; Dobran I; Hennersdorf M; Perings C; Heydthausen M; Winter J; Strauer BE
    Z Kardiol; 2000; 89 Suppl 3():194-205. PubMed ID: 10810803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective implantation of cardioverter-defibrillators in patients with genetic heart disease and sudden death risk.
    Kamath GS; Mittal S; Sherrid MV
    Anadolu Kardiyol Derg; 2009 Dec; 9 Suppl 2():32-40. PubMed ID: 20089485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II.
    Klein H; Auricchio A; Reek S; Geller C
    Am J Cardiol; 1999 Mar; 83(5B):91D-97D. PubMed ID: 10089848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of traditional and biventricular implantable cardiac devices for primary and secondary prevention of sudden death.
    Klein MH; Gold MR
    Cardiol Clin; 2008 Aug; 26(3):419-31, vi-vii. PubMed ID: 18538188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic role of post-infarction C-reactive protein in patients undergoing implantation of cardioverter-defibrillators: design of the C-reactive protein Assessment after Myocardial Infarction to GUide Implantation of DEfibrillator (CAMI GUIDE) study.
    Bellocci F; Biasucci LM; Gensini GF; Padeletti L; Raviele A; Santini M; Giubilato G; Landolina M; Biondi-Zoccai G; Raciti G; Sassara M; Castro A; Kheir A; Crea F
    J Cardiovasc Med (Hagerstown); 2007 Apr; 8(4):293-9. PubMed ID: 17413310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.